From a Parkinson's disease expert: Rasagiline and the Future of Therapy
Open Access
- 1 January 2007
- journal article
- Published by Springer Science and Business Media LLC in Molecular Neurodegeneration
- Vol. 2 (1), 13
- https://doi.org/10.1186/1750-1326-2-13
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Modification of L-DOPA pharmacological activity by MAO inhibitorsJournal of Neural Transmission, 2007
- Rasagiline enhances l-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pigNeuropharmacology, 2004
- Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitorNeuroReport, 1998
- Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In VivoJournal of Neurochemistry, 1996
- Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortexNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1993
- RELATIONSHIP BETWEEN TYRAMINE POTENTIATION AND SELECTIVE INHIBITION OF MONOAMINE OXIDASE TYPES A AND B IN THE RAT VAS DEFERENSBritish Journal of Pharmacology, 1982